Soleno Therapeutics (SLNO) EBIT: 2013-2017
Historic EBIT for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$5.2 million.
- Soleno Therapeutics' EBIT fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.49%. This contributed to the annual value of -$187.7 million for FY2024, which is 353.49% down from last year.
- Soleno Therapeutics' EBIT amounted to -$5.2 million in Q4 2017, which was down 97.61% from -$2.6 million recorded in Q3 2017.
- Over the past 5 years, Soleno Therapeutics' EBIT peaked at -$559,783 during Q4 2013, and registered a low of -$5.2 million during Q4 2017.
- Moreover, its 3-year median value for EBIT was -$2.8 million (2017), whereas its average is -$2.9 million.
- As far as peak fluctuations go, Soleno Therapeutics' EBIT tumbled by 254.68% in 2015, and later skyrocketed by 67.79% in 2017.
- Over the past 5 years, Soleno Therapeutics' EBIT (Quarterly) stood at -$559,783 in 2013, then crashed by 229.72% to -$1.8 million in 2014, then crashed by 89.99% to -$3.5 million in 2015, then spiked by 47.73% to -$1.8 million in 2016, then slumped by 183.62% to -$5.2 million in 2017.
- Its last three reported values are -$5.2 million in Q4 2017, -$2.6 million for Q3 2017, and -$3.0 million during Q2 2017.